CFI-402411

CFI-402411 is a small molecule from Treadwell Therapeutics. An oral small-molecule inhibitor of HPK1, tested alone and with pembrolizumab in advanced solid tumours. Its furthest stage is phase 1, for advanced solid tumours. ClinicalTrials.gov registers it in one study linked below. Company pipeline lists TWT-101 as Phase 1 'Actively recruiting', but the registry record NCT04521413 shows overall status UNKNOWN (registered as phase 1/2); the company pipeline page appears out of date. Whether it works in people has not been established unless a trial below reports it.